Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.39 and traded as low as $2.18. Oramed Pharmaceuticals shares last traded at $2.20, with a volume of 73,060 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 13th.

Oramed Pharmaceuticals Trading Up 1.8 %

The firm has a market capitalization of $90.29 million, a price-to-earnings ratio of 20.36 and a beta of 1.67. The business has a 50-day moving average price of $2.38 and a two-hundred day moving average price of $2.39.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ORMP. BML Capital Management LLC lifted its stake in Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Oramed Pharmaceuticals during the 3rd quarter valued at $272,000. Dimensional Fund Advisors LP boosted its stake in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 10,774 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 9,242 shares during the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $81,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.